The Combination of Avelumab + Axitinib (Ave/Axi) in Advanced RCC: a legitimate 1st line contender

The Combination of Avelumab + Axitinib (Ave/Axi) in Advanced RCC: a legitimate 1st line contender

kidneycancer

1 year
161 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Toni K. Choueiri, MD Director, The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute discusses The Combination of Avelumab + Axitinib (Ave/Axi) in Advanced RCC: a legitimate 1st line contender at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia
Up Next Autoplay